The objective of the Pharmacology Core is to enable the projects in this Center to develop new classes of host-targeting antiviral therapeutics for the Priority viruses. The overall goal of this core is to provide the infrastructure that will enable compounds for each project to advance in pre-clinical development. This core will establish capabilities and a Center-focused collection of expertise and advisors, which are not available on the Stanford University campus or commercially. To achieve the above goals, the pharmacology core will accomplish the following specific aims, which are to provide: (i) Medicinal chemistry capabilities to produce compound series required for: characterization of lead compounds, their structure-activity-relationships, design and synthesis of pro-drugs, and analysis of drug metabolites. (ii) In vitro characterization of drug metabolism in murine and human systems. (iii) In vivo analysis of drug metabolism in conventional mice and in mice with humanized livers. (iv) In vivo analysis of drug efficacy in mice with humanized livers. (v) Biostatistical support for analysis of all data produced by the Program's projects and by the Pharmacology Core.
In summary, we seek to develop new classes of host-targeting antiviral therapeutics that are capable of treating multiple NIAID Emerging and Re-emerging Priority Pathogen viruses, when used alone or in combination with other available agents.
|Vallania, Francesco; Tam, Andrew; Lofgren, Shane et al. (2018) Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. Nat Commun 9:4735|
|Bongen, Erika; Vallania, Francesco; Utz, Paul J et al. (2018) KLRD1-expressing natural killer cells predict influenza susceptibility. Genome Med 10:45|
|Dovey, Cole M; Diep, Jonathan; Clarke, Bradley P et al. (2018) MLKL Requires the Inositol Phosphate Code to Execute Necroptosis. Mol Cell 70:936-948.e7|
|Pu, Szu-Yuan; Xiao, Fei; Schor, Stanford et al. (2018) Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res 155:67-75|
|Xiao, Fei; Wang, Stanley; Barouch-Bentov, Rina et al. (2018) Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release. MBio 9:|
|Sweeney, Timothy E; Azad, Tej D; Donato, Michele et al. (2018) Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters. Crit Care Med 46:915-925|
|Schor, Stanford; Einav, Shirit (2018) Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs. DNA Cell Biol 37:63-69|
|Cheung, Peggie; Vallania, Francesco; Warsinske, Hayley C et al. (2018) Single-Cell Chromatin Modification Profiling Reveals Increased Epigenetic Variations with Aging. Cell 173:1385-1397.e14|
|Haynes, Winston A; Tomczak, Aurelie; Khatri, Purvesh (2018) Gene annotation bias impedes biomedical research. Sci Rep 8:1362|
|Sweeney, Timothy E; Thomas, Neal J; Howrylak, Judie A et al. (2018) Multicohort Analysis of Whole-Blood Gene Expression Data Does Not Form a Robust Diagnostic for Acute Respiratory Distress Syndrome. Crit Care Med 46:244-251|
Showing the most recent 10 out of 73 publications